tweetindex
RU

Paras Sharma

@paras_biotech · Vancouver, British Columbia · joined 08 Jun 2010

In life science venture capital

17 475Followers
121Following
2 036Posts total
84.3KViews on collected posts

Последние посты

@paras_biotech What's the date of this report? 164 views · 1 likes · 0 reposts · 0 replies Open on X →
@paras_biotech the hard part isn’t generating another candidate it’s proving the model found a causal signal rather than a prettier shortcut through old assay bias what would make the result fail the lab test? 409 views · 1 likes · 0 reposts · 0 replies Open on X →
@paras_biotech Mostly them are just from Insilico which is using “Ai” to do me toos…. 457 views · 1 likes · 0 reposts · 0 replies Open on X →
From Bernstein: AI in Drug Discovery - separating the hype from the real goals & progress https://t.co/x02VX7rS36
23.9K views · 190 likes · 24 reposts · 10 replies Open on X →
@paras_biotech 71% of late-stage ADC programs on one payload class isn't diversification, it's a queue. CNS and pancreatic stay red because we keep lining up for validated linkers instead of new biology. 864 views · 4 likes · 1 reposts · 0 replies Open on X →
ADC field's uneven maturity: Diversification in targets, consolidation in payloads Source: https://t.co/YVsfkglVK5 https://t.co/byfwRW40LP
31.2K views · 137 likes · 29 reposts · 1 replies Open on X →
XBI: 2 decades of cycles and the 2026 clinical scorecard Green: Moderna–Merck's cancer vaccine; Retatrutide. Daraxonrasib. Aficamten Red: cardiology got crushed. Pelacarsen, eplontersen, abelacimab, ziltivekimab – all hit their biomarker, all failed to help patients. https://t.
3.5K views · 31 likes · 4 reposts · 1 replies Open on X →
Radiopharmaceutical pipeline on one grid -> Data Source: William Blair https://t.co/M88ST6UV9e
8.4K views · 92 likes · 20 reposts · 4 replies Open on X →
Biotech IPOs: Stage Mix & Performance Shifted from vol to quality: 74–78 listings in 20/21 produced -ve cohort returns, while smaller, more clinically mature cohorts since 2022 have delivered +24% to +143%. Fewer deals, later-stage assets, better performance Data Source: UBS ht
15.4K views · 50 likes · 4 reposts · 3 replies Open on X →

На фоне аккаунтов своего размера

9 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. показывается широко, но откликается мало кто.

Медианные просмотры3 475этот аккаунт924медиана для 10K–100K
Охват, %19.89%этот аккаунт3.62%медиана для 10K–100K
Вовлечённость, %0.58%этот аккаунт1.52%медиана для 10K–100K
ПоказательЭтот аккаунтМедиана для 10K–100KОтношение
Медианные просмотры на пост3 4759243.76×
Охват (просмотры ÷ подписчики)19.89%3.62%5.49×
Вовлечённость0.58%1.52%0.38×

Другие в этом диапазоне →   Сравнить с другим аккаунтом →   Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

15.4K29 Aug
8.4K5 Sep
3.5K8 Sep
31.2K12 Sep
864
23.9K20 Sep
457
409
164

Last 9 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.38%29 Aug
1.39%5 Sep
1.06%8 Sep
0.55%12 Sep
0.58%
0.95%20 Sep
0.22%
0.24%
0.61%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes44.5%507 in total
Reposts7.2%82 in total
Replies1.7%19 in total
Quotes1.0%11 in total
Bookmarks45.7%520 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Похожие аккаунты